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CHAPTER 11
Selenium and methionine sulfoxide reduction
Hwa-Young Kim & Vadim N. Gladyshev
Department of Biochemistry, University of Nebraska–Lincoln
Summary: Methionine residues in proteins can be readily oxidized to a diastereomeric 
mixture of methionine sulfoxides by reactive oxygen species. In  most  organisms, 
methionine  sulfoxides  are  reversibly  and stereospecifi cally reduced back to me-
thionine by two distinct classes of repair enzymes, methionine-S-sulfoxide reductase 
(MsrA) and methionine-R-sulfoxide reductase (MsrB). Methionine sulfoxide reduc-
tion is thought to be an essential pathway that protects cells from oxidative stress and 
regulates protein function. This pathway is also implicated in delaying the aging pro-
cess in organisms from yeast to mammals. The fi rst selenoprotein identifi ed using bio-
informatics methods, SelR (also known as SelX or MsrB1), was recently found to be a 
selenocysteine-containing MsrB. In mammals, selenoprotein MsrB1 is a major MsrB, 
while MsrB2 and MsrB3 contain cysteine in place of selenocysteine. It has been found 
that selenocysteine- and cysteine-containing MsrBs employ different catalytic mecha-
nisms. Interestingly, a selenocysteine-containing form of MsrA was also described, but 
so far was only detected in green algae.
Introduction
Selenium is an essential trace element in humans and other mammals. It is co-
translationally incorporated into proteins in the form of the 21st amino acid, 
selenocysteine (Sec) [1–3]. The Sec-containing proteins, selenoproteins, are 
found in all three kingdoms of life. Twenty fi ve selenoprotein genes have been 
identifi ed in human and 24 in rodent genomes [4]. A limited number of sele-
noproteins have been characterized while functions and physiological roles of 
many other selenoproteins have yet to be determined. Among selenoproteins 
with known functions the majority are oxidoreductases, for example, glutathi-
one peroxidase [5], thioredoxin reductase [6] and formate dehydrogenase [7]. 
Selenoproteins typically exhibit 100-1,000 fold higher enzyme activities than 
their cysteine (Cys) mutants or natural Cys-containing forms. A key reason 
for the use of Sec in biological systems is explained by this high catalytic ac-
tivity of Sec-containing enzymes. For incorporation of Sec at in-frame UGA 
codons, cis- and trans-acting factors are required, including Sec insertion se-
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quence (SECIS) element, SECIS-binding proteins, tRNA[Ser]Sec, and Sec-spe-
cifi c elongation factor [3,8].
In 1999, initial bioinformatics methods were developed for identifi cation 
of selenoprotein genes by searching for SECIS elements (see Chapter 9). The 
fi rst selenoprotein identifi ed using this approach was designated as selenopro-
tein R (SelR) [9]. Independently, it was described as selenoprotein X (SelX) 
[10]. Comparative genomic analyses were then used to link the function of 
SelR to the pathway of methionine sulfoxide reduction, and this prediction 
was verifi ed experimentally [11].
Proteins can be oxidized by reactive oxygen species (ROS) generated in 
cells during stress and physiological processes. Methionine residues in pro-
teins are among the most susceptible to oxidation by ROS and are converted 
by these species to methionine sulfoxide. A diastereomeric mixture of methio-
nine-S-sulfoxide and methionine-R-sulfoxide is generated by ROS because of 
the presence of chiral sulfur in methionine sulfoxides [12]. Generation of me-
thionine sulfoxides may manifest signifi cant structural and functional changes 
in proteins. However, methionine sulfoxide can be reduced back to methio-
nine by repair enzymes, methionine sulfoxide reductases. Therefore, methio-
nine sulfoxide reduction is thought to be an important pathway that protects 
cells against oxidative stress, regulates protein function, and delays the aging 
process [13-17].
This chapter will focus on methionine sulfoxide reduction in mammals and 
the role of selenium in this pathway.
Methionine sulfoxide reductases
Methionine sulfoxide reductases reduce free and protein-bound methionine 
sulfoxides back to methionine in the presence of thioredoxin (Trx) or dithioth-
reitol (DTT) [18,19]. To catalyze the repair process, two distinct stereospecifi c 
enzymes are evolved. MsrA can only reduce the S epimer of methionine sulf-
oxide, whereas MsrB is specifi c for the R form of this amino acid (Figure 1).
Most organisms from bacteria to humans contain MsrA and MsrB genes 
in their genomes. However, some hyperthermophiles and intracellular para-
sites do not have MsrA, MsrB, or both proteins [11]. While parasites have ac-
cess to metabolic pathways of the host, the reason why certain organisms that 
live at high temperatures lack the methionine sulfoxide reduction system is 
not understood. MsrA and MsrB genes are clustered in several bacterial ge-
nomes and often form an operon. Furthermore, MsrA and MsrB activities are 
often detected in a single polypeptide formed via direct MsrA/MsrB fusion 
[11,20]. Single MsrA and MsrB genes are present in yeast (e.g., Saccharomy-
ces cerevisiae) and many animals (e.g., Caenorhabditis elegans and Drosoph-
ila melanogaster) [11]. On the other hand, multiple MsrA and/or MsrB genes 
have been identifi ed in the plant kingdom, for example in Arabidopsis thali-
ana [21,22] and Chlamydomonas reinhardtii [23].
MsrA was discovered decades ago, and its function, catalytic mechanism, 
and structure are well understood [18,19,24–29]. MsrB has only recently been 
identifi ed and is currently being extensively characterized [11,30–34].
Mammalian methionine sulfoxide reductases
Human and mouse genomes contain a single MsrA gene [35]. Mammalian 
MsrA has a typical N-terminal mitochondrial targeting peptide. Interestingly, 
however, this protein is located in cytosol and nucleus as well as in mitochon-
dria [36-38]. Although molecular mechanisms responsible for targeting this 
protein to different cellular compartments are not fully understood, a recent 
study has shown that structural and functional elements of MsrA play a role in 
subcellular occurrence of this protein [38].
In contrast to a single MsrA gene [39,40], there are three MsrB genes in 
mammals [41]. MsrB1 (also known as selenoprotein R or selenoprotein X) 
[9,10] is a selenoprotein in which Sec occupies the active site. This protein re-
sides in the cytosol and nucleus. The other two MsrBs are homologous pro-
teins in which Cys residues are present in place of Sec. MsrB2 (also known as 
CBS-1) [32,42] is a mitochondrial protein. Interestingly, human MsrB3 occurs 
Figure 1. A pathway of methionine sulfoxide reduction. R and S diastereomers of me-
thionine sulfoxide are formed directly or indirectly in free methionines and protein 
methionine residues in the presence of oxidants, such as hydrogen peroxide. Methio-
nine-S-sulfoxides are reduced by MsrA and methionine-R-sulfoxides by MsrB with re-
ductants, such as thioredoxin.
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in two protein forms, MsrB3A and MsrB3B. These two forms are generated 
by alternative splicing of the fi rst exon. The MsrB3A is targeted to the endo-
plasmic reticulum (ER), whereas MsrB3B is targeted to mitochondria [41]. 
However, there is no evidence for alternative splicing in the mouse MsrB3 
gene. This protein contains the N-terminal ER signal followed by the mito-
chondrial signal sequence in a single coding region. This mouse MsrB3 form 
resides in the ER [43]. These fi ndings of multiple cellular locations of MsrA 
and MsrB suggest that different compartments in mammalian cells maintain 
the methionine reduction system to repair oxidized methionine residues.
Physiological roles of methionine sulfoxide reductases
Reversible interconversion between methionine and methionine sulfoxide 
residues is implicated in several biological processes. Previously proposed 
functions of methionine sulfoxide reductases include repair of damaged pro-
teins, antioxidant function as scavengers of ROS, and regulation of protein 
function [44,45].
A number of published reports describe the role of methionine sulfoxide 
reductases in antioxidant defense. For example, overexpression of MsrA pro-
tected S. cerevisiae and human T cells against oxidative stress [46], and the cor-
responding homologs were implicated in the protection against ROS in many 
microorganisms, such as Neisseria gonorrhoeae [47], Staphylococcus aureus 
[48], and Helicobacter pylori [49]. Recently, MsrA was found to promote vi-
ability of lens cells [50] and retinal pigmented epithelial cells [51] by confer-
ring resistance to oxidative stress. In addition, MsrA can play a protective role 
against hypoxia/reoxygenation-mediated neuronal cell injury [52]. Lens MsrBs 
were also found to play a role in resistance to oxidative stress [53]. In addition, 
A. thaliana MsrA was reported to repair oxidatively damaged proteins during 
dark by reducing methionine sulfoxides in these proteins [21].
Methionine sulfoxide reduction and aging
Methionine sulfoxide reductases are directly implicated in regulation of the 
aging process. Research in this area has focused mainly on the effects of 
MsrA. Deletion of the MsrA gene in mice decreased the lifespan by 40% [54], 
whereas overexpression of MsrA in Drosophila extended it by 70% [55]. The 
data that MsrA regulates lifespan in a variety of organisms raise a possibility 
that MsrB may also play an important role in the aging process. In particular, 
an attractive hypothesis has been advanced that since MsrB1 is a selenopro-
tein, dietary selenium supplementation may be used to increase expression of 
this protein. If MsrB1 regulates lifespan, elevated levels of this protein due to 
increased dietary intake of selenium may promote longevity in certain organ-
isms or genetic backgrounds.
The role of MsrB in aging has recently been tested using S. cerevisiae as a 
model organism [56]. This protein was found to extend the yeast lifespan un-
der caloric restriction conditions, whereas MsrA was most effi cient under nor-
mal growth conditions. The lifespan extension required oxygen because it was 
found that neither MsrA nor MsrB regulate the lifespan of yeast cells grown 
under anaerobic conditions. In the future, deletion or overexpression of MsrB 
genes in mammals is needed to investigate the roles of these proteins in mam-
malian aging. Characterization of the effect of overexpression of MsrA on the 
lifespan in a mouse model also should be informative.
In addition to regulating lifespan, methionine sulfoxide reductases were 
directly implicated in aging-related neurodegenerative diseases, such as Al-
zheimer’s and Parkinson’s diseases [57-59].
Selenoprotein forms of methionine sulfoxide reductases
Although MsrBs are widely distributed in nature, the selenoprotein form of 
MsrB has only been found in vertebrates. In contrast, vertebrate MsrAs are 
Cys-containing proteins. Interestingly, a selenoprotein form of MsrA has also 
been identifi ed, but could only be detected in C. reinhardtii, a unicellular 
green algae [23]. This Sec-containing MsrA has not been characterized. The 
observation that both classes of methionine sulfoxide reductase can occur in 
the form of selenoproteins suggests a catalytic advantage that Sec can offer in 
protection against oxidation of methionine residues.
Catalytic properties and key role of selenium in MsrB
Both bacteria and eukaryotes share basic features of the Sec insertion machin-
ery, such as SECIS element, Sec tRNA, and SECIS-binding protein. However, 
a bacterial Sec insertion system also signifi cantly differs from the mammalian 
system [3, 60–63]. For example, the conserved sequences and structures of 
SECIS elements are different in bacteria and eukaryotes. The location of these 
structures is also different: bacterial SECIS elements are present within cod-
ing regions, immediately downstream of Sec-coding UGA codons, whereas 
eukaryotic SECIS elements are located in the 3’-untranslated regions.
What is the role of the Sec residue in catalytic function of mammalian 
MsrB1? By site-directed mutagenesis, a bacterial SECIS element was intro-
duced immediately downstream of the in-frame UGA Sec codon, and the re-
combinant Sec-containing MsrB1 was expressed in Escherichia coli [41]. 
This recombinant selenoprotein MsrB1 had four mutations (S99R, S100L, 
K102G, and F103P) compared to the wild type Sec-containing protein. The 
mutant exhibited ~800-fold higher enzyme activity than the corresponding 
Cys-containing form, indicating the essential role of Sec in this enzyme. In 
addition, a separate study reported that a recombinant Sec-containing MsrB1 
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expressed from a construct that contained the entire E. coli formate dehy-
drogenase H SECIS element in the coding region, had 100-200 fold higher 
specifi c activity than the corresponding Cys mutant [64]. However, natural 
mammalian Cys-containing enzymes, MsrB2 and MsrB3, also showed a high 
enzyme activity [41].
Although the primary function of MsrA and MsrB is to catalyze the reduc-
tion of protein-based methionine sulfoxides, these enzymes can also reduce 
free methionine sulfoxides, albeit with low activity. Consistent with this prop-
erty, all three mammalian MsrBs exhibited the activity in the conversion of 
free methionine-R-sulfoxide to methionine [41].
Some but not all MsrBs are zinc-containing proteins. This group of pro-
teins includes all animal MsrBs, which contain a structural zinc coordinated 
by two CXXC motifs (two Cys separated by two other residues) [11,41]. Mu-
tation of any zinc-coordinating Cys to Ser in Drosophila MsrB resulted in 
complete loss of metal and catalytic activity [34]. It has been suggested that 
zinc plays a structural role in metalloprotein MsrBs, and that this metal is not 
directly involved in the catalytic function [34,65].
Catalytic mechanisms of MsrB
The reaction mechanism of MsrA has been characterized biochemically and 
is well supported by 3D structures [25–29]. Studies involving MsrBs from 
D. melanogaster, N. gonorrhoeae, and N. meningitides [24,34,66] revealed 
a similar catalytic mechanism. Interestingly, MsrA and MsrB folds are com-
pletely different [24,26-28,67]. MsrB functions in the following manner: 1) a 
catalytic Cys attacks sulfoxide moiety of the substrate resulting in the forma-
tion of sulfenic acid intermediate and concomitant release of methionine; 2) a 
resolving Cys attacks the sulfenic acid intermediate to form an intramolecu-
lar disulfi de bond; and 3) a fully reduced enzyme is regenerated by reduction 
of the disulfi de with Trx, a natural electron donor. DTT can also reduce the di-
sulfi de in in vitro assays.
Multiple sequence alignments showed that ~60% of known MsrBs con-
tain the conserved resolving Cys. The remaining ~40% of MsrB, including 
all three mammalian MsrBs, do not have this Cys. In addition, some bacte-
rial MsrBs have only a single Cys in their sequences, suggesting the lack of 
any resolving Cys. How does the reaction proceed in these enzymes? Two al-
ternative reaction mechanisms have been proposed. One is a direct reduction 
of the sulfenic acid intermediate by Trx. The other is the use of an alternative 
resolving Cys to form the intramolecular disulfi de bond with the catalytic 
Cys. The second possibility is supported by the recent study of Xanthomonas 
campestris MsrB [68].
Different sets of active site features in selenoprotein and 
non-selenoprotein MsrB
Multiple sequence alignments reveal three highly conserved residues in MsrB 
sequences. These three residues are present in Cys-containing MsrBs, but ab-
sent in selenoprotein forms of this enzyme (Figure 2). It was previously found 
that these residues are part of the active site. Why did selenoprotein MsrBs 
evolve different residues in these positions? What are the roles of these resi-
dues in the catalytic function of selenoprotein and Cys-containing MsrBs?
It was recently found that the three residues uniquely conserved in Cys-con-
taining MsrBs are critical for enzyme activity in MsrB2 and MsrB3, yet intro-
ducing these residues into MsrB1 inactivates this selenoprotein. Interestingly, 
when these residues are introduced into the Cys-containing mutant of MsrB1, 
the activity of this mutant increases several fold. Thus, the three residues are 
required for Cys-containing MsrB forms, but detrimental for the Sec-contain-
Figure 2. Partial alignment of Sec- and Cys-containing MsrBs. Catalytic Cys (C) and 
Sec (U) residues are shown by an arrow. The conserved His, Val/Ile, and Asn residues 
in Cys-containing proteins are indicated by arrowheads, and the corresponding res-
idues (Gly, Glu, and Phe, respectively) in mouse selenoprotein MsrB1 are indicated 
by bold letters. Numbering of ammo acids is based on the mouse MsrB1 sequence. 
Cys71 and Cys74 coordinate zinc, and the corresponding CxxC motif is conserved 
in many, but not all MsrBs. Accession numbers (GI) are as follows: Mus musculus 
MsrB1, 7305478; M. musculus MsrB2, 27753987; Homo sapiens MsrB3, 72534836; 
Drosophila melanogaster, 17944415; Saccharomyces cerevisiae, 6319816; Arabidop-
sis thaliana, 4115939; Escherichia coli, 15802192; Methanothermobacter thermau-
totrophicus, 15678738; Agrobacterium tumefaciens, 15888246; Mycobacterium tu-
berculosis, 15609811; Salmonella enterica, 16760604; Vibrio cholerae, 15642000; 
Helicobacter pylori, 3252888; Hemophilus infl uenzae, 16273361; Neisseria gonor-
rhoeae, 19526685.
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ing forms. These data suggested that Sec- and Cys-containing MsrBs evolve 
distinct sets of active site features to maximize their catalytic effi ciencies.
Different catalytic mechanisms between selenoprotein and 
non-selenoprotein mammalian MsrBs
As discussed above, many selenoproteins have fully functional orthologs, 
wherein Cys replaces Sec. These Cys orthologs are often catalytically as ef-
fi cient as selenoprotein forms. The reason why Sec is used in proteins if the 
Cys versions are suffi cient for their functions is only beginning to be under-
stood. The three mammalian MsrBs offer a great model system to address 
these questions which are central to the role of selenium in biology. We re-
cently reported that selenoprotein and non-selenoprotein forms of mammalian 
MsrBs employ different catalytic mechanisms with respect to the regeneration 
of the fully reduced proteins (Figure 3) [69].
As shown in Figure 3, the selenoprotein MsrB1 requires a unique resolving 
Cys for recycling of the enzyme. A selenenic acid intermediate of MsrB1 is en-
gaged in a selenenylsulfi de bond with resolving Cys located in the N-terminal 
part of the protein. Mutation of this Cys to Ser results in complete loss of en-
zyme activity in the Trx-dependent reaction but not in the DTT-dependent reac-
tion. Subsequently, the selenenylsulfi de is reduced by a physiological electron 
donor, Trx. It appears that the selenenic acid intermediate cannot be reduced by 
Trx but is reducible by DTT. In contrast, mutational analyses revealed that the 
resolving Cys is not needed for Cys-containing MsrB2 and MsrB3, in which 
the sulfenic acid intermediate is likely directly reduced by Trx.
Catalytic advantages and disadvantages of Sec-containing proteins 
compared to Cys-containing counterparts
The data on Sec- and Cys-containing MsrBs suggested that Sec per se may 
result in a higher catalytic activity. Replacement of Cys with Sec in mam-
malian MsrB2 and MsrB3 increased the activity over 100 fold in the DTT-
dependent reaction [69]. It has been previously reported that the catalytic 
activity of phospholipid hydroperoxide glutathione peroxidase can also be 
increased by replacing the active site Cys with Sec [70]. Thus, the enhanced 
catalytic activity of selenoproteins can explain, at least in part, the advantage 
of Sec over Cys. However, replacement of Cys with Sec may not only in-
fl uence enzyme activity, but also alter protein function. For instance, a Sec-
containing form of subtilisin is an effi cient peroxidase rather than a protease 
[71]. The use of Sec in glutathione S-transferase also changed this protein to 
a peroxidase [72].
Are there any other advantages of the use of selenium besides enhancing 
enzyme activity? A recent study has shown that the presence of a unique C-
terminal active site in Drosophila thioredoxin reductase (SCCS instead of 
GCUG in mammalian enzymes) can convert this protein into a highly active 
enzyme [73]. This study suggested that the advantages of selenoenzymes are 
in a broader range of substrates and fl exibility of microenvironmental condi-
tions in the active sites.
It appears that the use of Sec can also result in catalytic disadvantages. 
Although the mutant Sec-containing forms of MsrB2 and MsrB3 are charac-
terized by a 100-fold increased methionine sulfoxide reductase activity, re-
generation of the active enzymes by natural electron donor (e.g., Trx) is not 
possible [69]. However, by introducing a unique resolving Cys, the seleno-
protein form of MsrB3 can become as active as the natural Cys-containing en-
zyme in the Trx-dependent reaction [69].
Evolutionary implications
Most selenoprotein forms likely evolved by replacing catalytic Cys with Sec, 
which equips oxidoreductases with enhanced activity. However, this evo-
lutionary process is more complex than a simple change of a Cys codon to 
TGA. The changes must also involve the generation of SECIS elements. Fur-
thermore, Sec may evolve only in environments where selenium is present in 
suffi cient levels and in organisms with active Sec insertion system. Clearly, 
although replacement of catalytic redox Cys with Sec may be expected to 
enhance protein function, other requirements should be satisfi ed. These and 
other factors may limit the use of Sec in biological systems.
Figure 3. Models for catalytic mechanisms of Sec- and Cys-containing MsrBs. In Sec-
containing MsrB1, the catalytic Sec attacks the methionine-R-sulfoxide (Met-R-SO) to 
form a selenenic acid intermediate, which interacts with a resolving Cys and forms a 
selenenylsulfi de bond. This selenenylsulfi de bond, subsequently, is reduced by Trx. In 
contrast, in Cys-containing MsrB2 and MsrB3, a sulfenic acid intermediate can be di-
rectly reduced by Trx because the resolving Cys is dispensable.
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